科研助攻 | 肿瘤 “冷” 变 “热”?机制大盘点!
“冷热” 肿瘤如何划分
简单来讲,“冷”肿瘤缺乏先天免疫,而在“热” 肿瘤中,免疫细胞较为活跃,其内环境也被大量的 T 细胞所浸润。
以上的治疗方法中溶瘤病毒疗法以及肿瘤疫苗是被认为具有强大抗癌活性的新兴疗法。
溶瘤病毒疗法不仅能够选择性的使肿瘤溶解外,而且通过溶瘤病毒裂解肿瘤细胞而诱导释放的 TAA、PAMP、DAMP 等可以激活体内的先天性和适应性免疫反应,改变肿瘤的免疫微环境使冷肿瘤变为热肿瘤[23]。在实际的应用中,T-VEC 就被证实是可以有效治疗黑色素瘤的溶瘤病毒[24]。临床上联合应用帕博利珠单抗能增加黑色素瘤患者的 CD8+ 细胞浸润及活化[25]。
但无论是哪种治疗,最后都离不开肿瘤机制的探索,每一种机制的发现都会为我们的肿瘤治疗带来指导性的意义。
MCE 可提供 20,000+ 个用于肿瘤研究的相关产品及试剂,其中也包括肿瘤免疫微环境相关产品。
[1] Yuan-Tong Liu, et al. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021 Mar 11;11(11):5365-5386.
[2] Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
[3] Mi Y, et al. The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment. Front Immunol. 2020;11:737.
[4] Bonaventura P, et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019 Feb 8;10:168.
[5] Wallich R, et al. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature. 1985;315(6017):301–305.
[6] Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-216.
[7] Zhu S, et al. Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy. Pharmacol Res. 2020 Sep;159:104980.
[8] Vacchelli E, et al.. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science (2015) 350:972–8.
[9] Mariathasan S, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544-548.
[10] Toso A, et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. (2014) 9:75–89.
[11] Randolph GJ, et al. Migration of dendritic cell subsets and their precursors. Annu Rev Immunol. 2008;26:293-316.
[12] Hojo S, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 2007;67(10):4725-4731.
[13] Montoya M, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 99:3263–3271.
[14] Srivastava P, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells. Leuk Res. (2014) 38:1332.
[15] Zhang C, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. (2017) 8:533.
[16] Golden EB, et al. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11-17.
[17] Ribas A, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy [published correction appears in Cell. 2018 Aug 9;174(4):1031-1032]. Cell. 2017;170(6):1109-1119.e10.
[18] Bevers RFM, et al. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer (2004) 91:607–12.
[19] Khong A, et al. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol. (2012) 31:246–66.
[20] Ott PA, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature (2017) 547:217–221.
[21] Shrimali RK, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171-6180.
[22] Klein C, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Oncoimmunology (2017) 6:e1277306.
[23] Russell L, et al. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. Biodrugs. 2019;33:485-501
[24] Andtbacka R, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33:2780-8
[25] Ribas A, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170:1109-19.e10
[26] van der Burg SH, et al. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16:219-33.
[27]Ott P, Hu-Lieskovan S, Chmielowski B, et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020;183:347-62.e24